Food and Drug Administration in the first quarter of 2012. The Phase 1 randomized, double-blind, placebo-controlled study will evaluate the security, tolerability, and pharmacokinetics of single ascending doses of ACHN-975 in healthful volunteers. The scholarly research is funded under a agreement award to Achaogen by the Defense Medical Analysis and Development Program. A second Phase 1 research of multiple ascending dosages of ACHN-975 administered for 14 days is planned to follow the single dose study. ‘Our mission at Achaogen is normally to discover and develop antibiotics to take care of patients with life-threatening bacterial attacks,’ Hillan added.